Morgan Stanley Graphite Bio, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$2.24 - $2.66 $458,702 - $544,709	204,778 New	204,778 $536,000
Q4 2023 Feb 13, 2024	BUY	$2.24 - $2.66 $131,745 - $156,447	58,815 Added 40.29%	204,778 $536,000
Q3 2023 Nov 15, 2023	BUY	$2.18 - $2.77 $161,413 - $205,099	74,043 Added 102.95%	145,963 $361,000
Q2 2023 Aug 14, 2023	SELL	$2.47 - $3.38 $327,028 - $447,512	-132,400 Reduced 64.8%	71,920 $186,000
Q1 2023 May 15, 2023	BUY	$1.85 - $3.21 $312,690 - $542,560	169,022 Added 478.84%	204,320 $500,000
Q4 2022 Feb 14, 2023	BUY	$2.82 - $3.59 $11,209 - $14,270	3,975 Added 12.69%	35,298 $117,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $4.24 $1.94 Million - $2.92 Million	-689,121 Reduced 95.65%	31,323 $100,000
Q2 2022 Oct 27, 2022	BUY	$2.14 - $5.23 $337,713 - $825,346	157,810 Added 28.05%	720,444 $1.98 Million
Q2 2022 Aug 15, 2022	BUY	$2.14 - $5.23 $337,713 - $825,346	157,810 Added 28.05%	720,444 $1.98 Million
Q1 2022 Oct 27, 2022	SELL	$5.1 - $13.06 $804,831 - $2.06 Million	-157,810 Reduced 21.9%	562,634 $2.87 Million
Q1 2022 May 13, 2022	SELL	$5.1 - $13.06 $692,304 - $1.77 Million	-135,746 Reduced 19.44%	562,634 $2.87 Million
Q4 2021 Feb 14, 2022	BUY	$8.41 - $16.71 $2.39 Million - $4.76 Million	284,615 Added 68.79%	698,380 $8.68 Million
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $6.54 Million - $11.7 Million	413,765 New	413,765 $6.78 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.